Pharma News, 2022

Spero Therapeutics is laying off approximately 75% of its workforce as part of a restructuring operation in light of the U.S. Food and Drug Administration's expected rejection of its New Drug Appl...

Drug distributors McKesson, Cardinal Health and Amerisource Bergen have agreed to pay the state of Washington a total of $518 million to settle litigation over their alleged roles in fueling the op...

Bayer announced Tuesday that The U.S. Food and Drug Administration accepted its supplemental New Drug Application (sNDA) for Nubeqa as a potential treatment for metastatic hormone-sensitive prosta...

Phathom Pharmaceuticals is having a good week as the U.S. Food and Drug Administration approved two of its products for bacterial illnesses in adults. ...

The European Commission has granted marketing authorization for Idorsia’s Quviviq (daridorexant) for the treatment of adult patients with chronic insomnia disorder. ...

Teva Pharmaceuticals and Lupin have settled their patent dispute over Lupin’s generic version of Teva’s Huntington’s disease drug, Austedo (deutetrabenazine). ...

AbbVie is off to a strong start for 2022, driven by success from Skyrizi and Rinvoq, as well as the company’s neuroscience platform that includes its depression treatments and its three-pronged a...

The U.S. Food and Drug Administration is quickly catching up after COVID-19 disrupted typical review timelines and planned inspections and it's bad news for three companies. 

Pfizer’s oral COVID-19 treatment Paxlovid (nirmatrelvir and ritonavir) failed to show meaningful improvements in people who took it after exposure to COVID-19.

It has taken French rare disease specialist Orphalan 11 years to earn its first approval in the U.S. 

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced ...

Tirzepatide (5 mg, 10 mg, 15 mg) achieved superior weight loss compared to placebo at 72 weeks of treatment in topline results from Eli Lilly and Company's (NYSE: LLY) SURMOUNT-1 clinical trial, w...